Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells

Efrat Harel; Abraham Rubinstein; Weibin Chen; Eli Breuer; Boaz Tirosh

doi:10.1016/j.bmcl.2010.09.048

Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells

Efrat Harel, Abraham Rubinstein, Weibin Chen, Eli Breuer^*, Boaz Tirosh

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Some carbamoylphosphonates (CPOs) inhibit matrix metalloproteinases (MMPs). Although MMPs are involved in inflammatory processes, the anti-inflammatory activity of CPOs has not been reported. In this context we compared the biological activity of the three aminoCPOs, PYR-CPO, PIP-CPO and cis-ACCP. We were particularly interested in their capability to modulate the secretion of tumor necrosis factor alpha (TNFα). LPS-activated mouse peritoneal macrophages and LPS-activated mouse splenocytes were used to explore this question. It was found that the aminoCPOs were able to reduce TNFα secretion to a level equivalent to the reduction caused by the steroid drug budesonide (BUD). The reduction in TNFα levels was neither accompanied by cytotoxicity, nor did it inhibit cell proliferation. To explicate whether the aminoCPOs affect TNFα processing by TNFα-converting enzyme (TACE), TACE inhibitory properties of the three molecules was tested in vitro. Only PIP-CPO exerted TACE inhibitory activity at therapeutic (non-cytotoxic) concentrations, indicating on its potential to serve as an anti-inflammatory agent by reducing TNFα secretion.

Original language	English
Pages (from-to)	6518-6523
Number of pages	6
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	20
Issue number	22
DOIs	https://doi.org/10.1016/j.bmcl.2010.09.048
State	Published - 15 Nov 2010

Bibliographical note

Funding Information:
The skillful assistance of Mrs. Rivka Hadar is greatly acknowledged. This work was supported in part by the Ministry of Science of Israel, in part by The German Israeli Foundation for Scientific Research and Development (GIF), and in part by the Grass Center for Drug Design and Synthesis of Novel Therapeutics to EB AR, BT and EB are affiliated with the David R. Bloom Center of Pharmacy, in the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem. BT is affiliated with the Dr. Adolf and Klara Brettler Centre for Research in Molecular Pharmacology and Therapeutics at the Hebrew University.

Keywords

Carbamoylphosphonate
Inflammation
Matrix metalloproteinase inhibitor
Phosphonate
TACE
TNFα

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.bmcl.2010.09.048

Cite this

@article{95de165a0cd0483db84184fa836a3d73,

title = "Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells",

abstract = "Some carbamoylphosphonates (CPOs) inhibit matrix metalloproteinases (MMPs). Although MMPs are involved in inflammatory processes, the anti-inflammatory activity of CPOs has not been reported. In this context we compared the biological activity of the three aminoCPOs, PYR-CPO, PIP-CPO and cis-ACCP. We were particularly interested in their capability to modulate the secretion of tumor necrosis factor alpha (TNFα). LPS-activated mouse peritoneal macrophages and LPS-activated mouse splenocytes were used to explore this question. It was found that the aminoCPOs were able to reduce TNFα secretion to a level equivalent to the reduction caused by the steroid drug budesonide (BUD). The reduction in TNFα levels was neither accompanied by cytotoxicity, nor did it inhibit cell proliferation. To explicate whether the aminoCPOs affect TNFα processing by TNFα-converting enzyme (TACE), TACE inhibitory properties of the three molecules was tested in vitro. Only PIP-CPO exerted TACE inhibitory activity at therapeutic (non-cytotoxic) concentrations, indicating on its potential to serve as an anti-inflammatory agent by reducing TNFα secretion.",

keywords = "Carbamoylphosphonate, Inflammation, Matrix metalloproteinase inhibitor, Phosphonate, TACE, TNFα",

author = "Efrat Harel and Abraham Rubinstein and Weibin Chen and Eli Breuer and Boaz Tirosh",

note = "Funding Information: The skillful assistance of Mrs. Rivka Hadar is greatly acknowledged. This work was supported in part by the Ministry of Science of Israel, in part by The German Israeli Foundation for Scientific Research and Development (GIF), and in part by the Grass Center for Drug Design and Synthesis of Novel Therapeutics to EB AR, BT and EB are affiliated with the David R. Bloom Center of Pharmacy, in the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem. BT is affiliated with the Dr. Adolf and Klara Brettler Centre for Research in Molecular Pharmacology and Therapeutics at the Hebrew University. ",

year = "2010",

month = nov,

day = "15",

doi = "10.1016/j.bmcl.2010.09.048",

language = "אנגלית",

volume = "20",

pages = "6518--6523",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Ltd.",

number = "22",

}

TY - JOUR

T1 - Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells

AU - Harel, Efrat

AU - Rubinstein, Abraham

AU - Chen, Weibin

AU - Breuer, Eli

AU - Tirosh, Boaz

N1 - Funding Information: The skillful assistance of Mrs. Rivka Hadar is greatly acknowledged. This work was supported in part by the Ministry of Science of Israel, in part by The German Israeli Foundation for Scientific Research and Development (GIF), and in part by the Grass Center for Drug Design and Synthesis of Novel Therapeutics to EB AR, BT and EB are affiliated with the David R. Bloom Center of Pharmacy, in the School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem. BT is affiliated with the Dr. Adolf and Klara Brettler Centre for Research in Molecular Pharmacology and Therapeutics at the Hebrew University.

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Some carbamoylphosphonates (CPOs) inhibit matrix metalloproteinases (MMPs). Although MMPs are involved in inflammatory processes, the anti-inflammatory activity of CPOs has not been reported. In this context we compared the biological activity of the three aminoCPOs, PYR-CPO, PIP-CPO and cis-ACCP. We were particularly interested in their capability to modulate the secretion of tumor necrosis factor alpha (TNFα). LPS-activated mouse peritoneal macrophages and LPS-activated mouse splenocytes were used to explore this question. It was found that the aminoCPOs were able to reduce TNFα secretion to a level equivalent to the reduction caused by the steroid drug budesonide (BUD). The reduction in TNFα levels was neither accompanied by cytotoxicity, nor did it inhibit cell proliferation. To explicate whether the aminoCPOs affect TNFα processing by TNFα-converting enzyme (TACE), TACE inhibitory properties of the three molecules was tested in vitro. Only PIP-CPO exerted TACE inhibitory activity at therapeutic (non-cytotoxic) concentrations, indicating on its potential to serve as an anti-inflammatory agent by reducing TNFα secretion.

AB - Some carbamoylphosphonates (CPOs) inhibit matrix metalloproteinases (MMPs). Although MMPs are involved in inflammatory processes, the anti-inflammatory activity of CPOs has not been reported. In this context we compared the biological activity of the three aminoCPOs, PYR-CPO, PIP-CPO and cis-ACCP. We were particularly interested in their capability to modulate the secretion of tumor necrosis factor alpha (TNFα). LPS-activated mouse peritoneal macrophages and LPS-activated mouse splenocytes were used to explore this question. It was found that the aminoCPOs were able to reduce TNFα secretion to a level equivalent to the reduction caused by the steroid drug budesonide (BUD). The reduction in TNFα levels was neither accompanied by cytotoxicity, nor did it inhibit cell proliferation. To explicate whether the aminoCPOs affect TNFα processing by TNFα-converting enzyme (TACE), TACE inhibitory properties of the three molecules was tested in vitro. Only PIP-CPO exerted TACE inhibitory activity at therapeutic (non-cytotoxic) concentrations, indicating on its potential to serve as an anti-inflammatory agent by reducing TNFα secretion.

KW - Carbamoylphosphonate

KW - Inflammation

KW - Matrix metalloproteinase inhibitor

KW - Phosphonate

KW - TACE

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=77958056213&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2010.09.048

DO - 10.1016/j.bmcl.2010.09.048

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 20889339

AN - SCOPUS:77958056213

SN - 0960-894X

VL - 20

SP - 6518

EP - 6523

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

IS - 22

ER -

Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this